Living with Psoriasis

Paranzino, Michael
September 2004
FDA Consumer;Sep2004, Vol. 38 Issue 5, p40
Reflects on life as a psoriasis patient. Characterization of the disease; Physical and emotional effects of psoriasis; Increase in the efforts of the U.S. government to develop psoriasis treatment.


Related Articles

  • Offer systemic therapy as first-line defense. Rutledge, Barbara J. // Dermatology Times;Sep2005 Supplement 4, Vol. 25, pS16 

    Evaluates the efficacy of alefacept therapy as first-line defense for psoriasis. Impact of psoriasis on the quality of life of the patient; Number of people affected with the disease of the year; Treatment paradigms for psoriasis.

  • Biologics' efficacy data growing. Jesitus, John // Dermatology Times;Sep2005 Supplement 4, Vol. 25, pS19 

    Reports on the advantages of longer treatment regimens and combinations with other modalities by use of biologic drugs for psoriasis treatment. Problems of alefacept; Observations on patients treated with alefacept; Advantages of combined therapies for psoriasis.

  • Clinical Characteristics Associated with Illness Perception in Psoriasis. WAHL, Astrid K.; ROBINSON, Hilde S.; LANGELAND, Eva; LARSEN, Marie H.; KROGSTAD, Anne-Lene; MOUM, Torbjørn // Acta Dermato-Venereologica;May2014, Vol. 94 Issue 3, p271 

    Knowledge of illness perception may aid the identification of groups of patients with a higher risk of coping poorly with the demands of their illness. This study aims to investigate associations between illness perception, clinical characteristics, patient knowledge, quality of life and...

  • THE PATIENT'S PERSPECTIVE. . Pickering, Henry // British Journal of General Practice;Feb2010, Vol. 60 Issue 571, p140 

    A personal narrative is presented which explores the author's experience of having psoriasis, particularly citing various drugs he used to treat the disease such as Betnovate cream, butazolidin and Acitretin.

  • Treatment failure rate, costs high in moderate-to-severe psoriasis.  // PharmacoEconomics & Outcomes News;3/12/2005, Issue 473, p8 

    Presents information on high medical costs observed among patients with moderate-to-severe psoriasis in the U.S. Use of claims data to examine systemic prescription drug and healthcare service among patients with moderate-to-severe psoriasis to assess treatment failure rates and medical costs;...

  • I WEAR LONG-SLEEVED SHIRTS all year. Summerfield, Julie // Woman's Day (Australia Edition);9/23/2002, p38 

    Presents an article on a mother who had a psoriasis. Symptoms of the disease; Treatments.

  • Systemics remain relevant psoriasis Rx. Nataloni, Rochelle // Dermatology Times;Sep2005 Supplement 4, Vol. 25, pS18 

    Reports that systemic drugs, from cyclosporine to methotrexate has retained a relevant role in the treatment of psoriasis despite of all encompassing focus on biologics. Comments of Bruce E. Strober, assistant professor of dermatology in New York University School of Medicine, New York, on the...

  • No cure for psoriasis, but treatments can help. Pinette, Dr. Gilles // Saskatchewan Sage;Apr2004, Vol. 8 Issue 7, p13 

    Psoriasis is a common condition that causes red or purple scaly patches on your skin. Psoriasis is pronounced "sore-eye-a-sis." These patches may be thick with a rough surface, and may be on the knees, elbows and scalp or they may be widespread across the entire body. The exact cause of...

  • tazarotene.  // Royal Society of Medicine: Medicines;2002, p523 

    The article presents information on tazarotene which is chemically a derivative of retinol or vitamin A. This drug can be used to treat mild to moderate plaque psoriasis. Administration is by topical application. It should not be used in pregnancy or breast-feeding. Patients should wash hands...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics